Consistently, differential IGFBP2 expression in each histological type was prognostic with strong statistical significance; decreased expression extended median survival by 24% in astrocytoma and 106% in oligoastrocytoma, whereas increased expression shortened median survival by >70% for astrocytoma and oligoastrocytoma and >80% for oligodendroglioma (Figure 6D). Here, IGFBP2 is linked to oligodendroglioma.